 NEW YORK and PETACH TIKVA, Israel, Dec. 04, 2020 GLOBE NEWSWIRE -- Y-mAbs Therapeutics, Inc. Nasdaq: YMAB the Company or Y-mAbs a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer and Takeda Israel, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited TSE:4502NYSE:TAK Takeda announced today that they have entered into an exclusive license and distribution agreement for the registration and commercialization in Israel of DANYELZA for the treatment of patients with relapsedrefractory high-risk neuroblastoma and omburtamab for the treatment of pediatric patients with CNSleptomeningeal metastasis from neuroblastoma. DANYELZA naxitamab-gqgk was approved by the U.S. FDA on November 25, 2020. Additionally, Y-mAbs plans to resubmit the amended BLA for omburtamab for the treatment of pediatric patients with CNSleptomeningeal metastasis from neuroblastoma to the FDA by the end of 2020 or in early 2021. 